KLRK1 and plasma cell myeloma: In addition, when focusing only on ND patients, the expression of the NKG2D ligand, ULBP3, on BM myeloma cells negatively correlated with the expression level of NKG2D on both CD56bright and CD56dim NK cells in BM (Figure S4).